Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04196530 · ClinicalTrials.gov registry record · Phase 1

BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab

A Phase 1 study of Tumor, Solid, sponsored by Eikon Therapeutics.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target
5
Study locations

NCT04196530 is a Phase 1 study of Tumor, Solid that has completed, run by Eikon Therapeutics. The registered enrollment target is 40 participants, below the 240-participant average among 11 other Tumor, Solid trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04196530, a Phase 1 study of Tumor, Solid, has completed, sponsored by Eikon Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target
5
Study locations

Study Summary

A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors

Conditions Studied

Tumor, Solid

Interventions

  • DRUG Atezolizumab
  • DRUG BDB001 (EIK1001)

Study Locations (5)

Texas

  • NEXT Oncology - San Antonio
  • South Texas Accelerated Research Therapeutics (START) - San Antonio

California

  • Angeles Clinic - Los Angeles

Florida

  • Florida Cancer Specialists - Sarasota

Tennessee

  • Tennessee Oncology - Nashville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2019-11-21
Est. Completion 2024-08-15
Phase Phase 1

Sponsor

Eikon Therapeutics

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04196530

The ClinicalTrials.gov registry entry for NCT04196530 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 240-participant average among 11 other Tumor, Solid trials with a reported enrollment target (83% lower). The listed sponsor is Eikon Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tumor, Solid appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.

NCT04196530 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04196530 about?

NCT04196530 is a clinical study titled "BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab". A Phase 1 Open-label Dose Escalation Study of BDB001 in Combination with Atezolizumab in Subjects with Advanced Solid Tumors

What is the current status of trial NCT04196530?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-11-21. Estimated completion is 2024-08-15.

What conditions does trial NCT04196530 study?

This clinical trial studies the following conditions: Tumor, Solid.

What interventions are being tested in trial NCT04196530?

The interventions under investigation include: Atezolizumab (DRUG), BDB001 (EIK1001) (DRUG).

Who is sponsoring clinical trial NCT04196530?

This trial is sponsored by Eikon Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04196530 being conducted?

This trial has 5 study locations across California, Florida, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Tumor, Solid

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Tumor, Solid

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.